ID   UKE-1
AC   CVCL_0104
SY   UKE1; GM23245
DR   BTO; BTO:0004765
DR   EFO; EFO_0006307
DR   ArrayExpress; E-MTAB-2706
DR   cancercelllines; CVCL_0104
DR   Coriell; GM23245
DR   Cosmic; 1012055
DR   Cosmic; 1281361
DR   Cosmic; 1519161
DR   Cosmic; 1633514
DR   Cosmic; 2306996
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GEO; GSM1374976
DR   PharmacoDB; UKE1_1641_2019
DR   Wikidata; Q54990275
RX   PubMed=10640966;
RX   PubMed=16408098;
RX   PubMed=22829968;
RX   PubMed=25485619;
RX   PubMed=26589293;
CC   HLA typing: A*02:01,03:01; B*07:02,35:03; C*04:01,07:02; DQA1*01:02,04:01; DQB1*04:01,06:02; DRB1*08:01,15:01 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (PubMed=16408098).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Donor information: Patient had a essential thrombocythemia transformed into acute leukemia.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C3407; Essential thrombocythemia
DI   ORDO; Orphanet_3318; Essential thrombocythemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   59Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 25
//
RX   PubMed=10640966; DOI=10.1002/(SICI)1097-0142(20000115)88:2<344::AID-CNCR14>3.0.CO;2-6;
RA   Fiedler W., Henke R.P., Ergun S., Schumacher U., Gehling U.M.,
RA   Vohwinkel G., Kilic N., Hossfeld D.K.;
RT   "Derivation of a new hematopoietic cell line with endothelial features
RT   from a patient with transformed myeloproliferative syndrome: a case
RT   report.";
RL   Cancer 88:344-351(2000).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=22829968; DOI=10.1038/bcj.2012.11;
RA   Buors C., Douet-Guilbert N., Morel F., Lecucq L., Cassinat B., Ugo V.;
RT   "Clonal evolution in UKE-1 cell line leading to an increase in JAK2
RT   copy number.";
RL   Blood Cancer J. 2:e66.1-e66.3(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//